Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

Dawson James starts Mesoblast at buy; PT $14

Dawson James Securities initiated coverage of Mesoblast (NASDAQ:MESO; ASX:MSB) with a “buy” rating and $14 price target. The stock closed at $7.42 on Dec. 18. Mesoblast is using its proprietary technology platform to...

December 19, 2019

Markets

Roth starts X4 Pharma at buy; PT $20

Roth Capital Partners launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with a “buy” rating and $20 price target. The stock closed at $11 on Dec. 17. Analyst Zegbeh Jallah writes that her investment thesis is based...

December 18, 2019

Markets

Analysts downgrade and lower PTs for Aduro Biotech

William Blair downgraded Aduro Biotech (NASDAQ:ADRO) to “market perform” from “outperform” and H.C. Wainwright cut its price target for Aduro after Novartis removed Aduro’s intratumoral STING agonist, ADU-S100, from its...

December 18, 2019

Markets

HCW cuts Diffusion Pharma PT to $3.50 on dilution

H.C. Wainwright lowered its price target for Diffusion Pharmaceuticals (NASDAQ:DFFN) to $3.50 from $10, reflecting dilution from two recent financings. The stock closed at 41 cents on Dec. 17. Analyst Swayampakula...

December 18, 2019

Markets

SVB Leerink halves Adamas Pharma PT to $6

SVB Leerink lowered its price target for Adamas Pharmaceuticals (NASDAQ:ADMS) to $6 from $13, saying the mixed Phase 3 INROADS data are not good enough. In afternoon trading on Dec. 17, the stock was quoted at $4.15...

December 17, 2019

Markets

Analysts up ImmunoGen PTs on FDA accelerated approval pathway

Analysts for H.C. Wainwright and SVB Leerink raised their price targets for ImmunoGen (NASDAQ:IMGN) after the FDA advised that a new single-arm study in platinum-resistant ovarian cancer (prOC) could support accelerated...

December 17, 2019

Markets

SVB Leerink ups Wave Life Sciences PT to $46 from $40

SVB Leerink raised its price target for Wave Life Sciences (NASDAQ:WVE) to $46 from $40 after the FDA approved Sarepta Therapeutics’ (NASDAQ:SRPT) golodirsen for the treatment of Duchenne muscular dystrophy (DMD) in...

December 13, 2019

Markets

Analysts downgrade Correvio Pharma as FDA Adcom rejects Brinavess

Analysts for H.C. Wainwright, Mackie Research and Echelon Wealth Partners downgraded Correvio Pharma (NASDAQ:CORV) after the FDA Cardiovascular and Renal Drugs Advisory Committee voted 11-2 against recommending approval...

December 11, 2019

Markets

Mackie Research ups Theratechnologies to buy; holds PT at $6.50

Mackie Research upgraded Theratechnologies (TSX:TH; NASDAQ:THTX) to “buy” from “hold” but maintained its price target at $6.50 (Canadian), saying the current share price represents a favorable risk-reward situation...

December 11, 2019

Markets

Analysts raise Forty Seven price targets on 5F9 data

Analysts for H.C. Wainwright and BTIG raised their price targets for Forty Seven (NASDAQ:FTSV) after the company updated results from its ongoing Phase 1b clinical study of magrolimab (5F9) in combination with...

December 10, 2019

Markets

SVB Leerink starts 89bio at OP; PT $55

SVC Leerink initiated coverage of 89bio (NASDAQ:ETNB) with an “outperform” rating and $55 price target. The stock closed at $28.60 on Dec. 6. 89bio is developing a fibroblast growth factor (FGF) 21 analog, BIO89-100, in...

December 9, 2019

Markets

WB ups Diplomat Pharmacy to market perform

William Blair upgraded Diplomat Pharmacy (NYSE:DPLO) to “market perform” from “underperform” after UnitedHealth Group’s (NYSE:UNH) OptumRx agreed to acquire Diplomat for $4 a share. Shares of Diplomat were quoted at $3...

December 9, 2019

Markets

HCW starts Puma Biotechnology at buy; PT $15

H.C. Wainwright launched coverage of Puma Biotechnology (NASDAQ:PBYI) with a “buy” rating and $15 price target. The stock closed at $7.44 on Dec. 5. Puma has a marketed drug called Nerlynx, which was approved by the FDA...

December 6, 2019

Markets

Dawson James removes PT for ADMA Biologics

Dawson James Securities removed its prior $4 price target for ADMA Biologics (NASDAQ:ADMA) after the company reported third quarter financial results. The stock was changing hands at $4.09 in afternoon trading on Dec. 5...

December 5, 2019

Markets

Dawson James starts Check Cap at buy; PT $4

Dawson James Securities initiated coverage of Check Cap (NASDAQ:CHEK) with a “buy” rating and $4 price target. The stock closed at $1.39 on Dec. 4. The company has developed an imaging technology’ known as C-Scan, using...

December 5, 2019

Markets

BTIG ups Axsome Therapeutics PT to $48 from $25

BTIG raised its price target for Axsome Therapeutics (NASDAQ:AXSM) to $48 from $25 after the company announced positive Phase 2 data for its AXS-12 drug candidate for the treatment of cataplexy and excessive daytime...

December 4, 2019

Markets

BTIG starts STAAR Surgical at buy: PT $46

BTIG initiated coverage of STAAR Surgical (NASDAQ:STAA) with a “buy” rating and $46 price target. The stock closed at $36.82 on Dec. 3. “We believe STAAR owns a superior refractive surgery option to the current standard...

December 4, 2019

Markets

Piper Jaffray starts TELA Bio at OW; PT $17

Piper Jaffray initiated coverage of TELA Bio (NASDAQ:TELA) with an “overweight” rating and $17 price target. The stock closed at $12.31 on Dec. 2. TELA is a regenerative medicine company, with products used in hernia...

December 3, 2019

Markets

WB starts BeyondSpring at outperform

William Blair launched coverage of BeyondSpring (NASDAQ:BYSI) with an “outperform” rating. The stock closed at $12.45 on Dec. 2. According to analyst Andy Hsieh, the Street is “undervaluing the clinical potential” of...

December 3, 2019

Markets

BTIG starts Galera Therapeutics at buy; PT $30

BTIG launched coverage of Galera Therapeutics (NASDAQ:GRTX) with a “buy” rating and $30 price target. The stock closed at $12.53. Galera is focused on developing superoxide dismutase mimetics, first‐in‐class medicines...

December 2, 2019

Markets

SVB Leerink starts Centogene at OP; PT $21

SVB Leerink initiated coverage of Centogene NV (NASDAQ:CNTG) with an “outperform” rating and price target of $21.The stock closed at $12.97 on Nov. 29. “We see Centogene as a leader in rare disease diagnostics...

December 2, 2019

Markets

Brookline starts BioCardia at buy; PT $22

Brookline Capital Markets launched coverage of BioCardia (NASDAQ:BCDA) with a “buy” rating and $22 price target. Near the close of trading on Nov. 27, the stock was quoted at $4.55. BioCardia is a developing CardiAMP...

November 29, 2019

Subscribe